See more : EnviroGold Global Limited (NVRO.CN) Income Statement Analysis – Financial Results
Complete financial analysis of Neo-Concept International Group Holdings Limited (NCI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Neo-Concept International Group Holdings Limited, a leading company in the industry within the sector.
You may be interested
- Ten Entertainment Group plc (TEG.L) Income Statement Analysis – Financial Results
- Futaba Corporation (FUBAF) Income Statement Analysis – Financial Results
- Virginia Energy Resources Inc. (VEGYF) Income Statement Analysis – Financial Results
- Hostmore plc (MORRF) Income Statement Analysis – Financial Results
- Aditya Birla Sun Life Mutual F (NIFTYQLITY.BO) Income Statement Analysis – Financial Results
Neo-Concept International Group Holdings Limited (NCI)
Website: https://www.neo-ig.com
About Neo-Concept International Group Holdings Limited
Neo-Concept International Group Holdings Limited provides one-stop apparel solution in Hong Kong. The company offers a suite of services in the apparel supply chain, including market trend analysis, product design and development, raw material sourcing, production and quality control, and logistics management. It sells knitwear/apparel products under the les 100 ciels brand. The company serves brand owners, apparel sourcing agents, and online fashion retailers primarily located in North America, the United Kingdom, and Europe. Neo-Concept International Group Holdings Limited was incorporated in 2021 and is based in Kwun Tong, Hong Kong. Neo-Concept International Group Holdings Limited operates as a subsidiary of Neo-concept (BVI) Limited.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 174.20M | 347.45M | 240.54M | 182.58M |
| Cost of Revenue | 139.15M | 305.62M | 217.94M | 170.93M |
| Gross Profit | 35.05M | 41.83M | 22.59M | 11.65M |
| Gross Profit Ratio | 20.12% | 12.04% | 9.39% | 6.38% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 18.23M | 20.12M | 14.70M | 12.83M |
| Selling & Marketing | 3.13M | 2.63M | 3.13M | 1.80M |
| SG&A | 21.36M | 22.75M | 17.83M | 14.63M |
| Other Expenses | 4.64M | 2.59M | 2.90M | 2.22M |
| Operating Expenses | 26.00M | 22.90M | 15.81M | 13.86M |
| Cost & Expenses | 165.16M | 328.52M | 233.75M | 184.79M |
| Interest Income | 92.95K | 1.00 | 1.00 | 0.00 |
| Interest Expense | 5.76M | 6.13M | 2.49M | 2.87M |
| Depreciation & Amortization | 3.41M | 18.96K | 37.04K | 319.74K |
| EBITDA | 14.90M | 21.67M | 1.28M | -4.94K |
| EBITDA Ratio | 8.56% | 6.24% | 4.15% | 0.19% |
| Operating Income | 9.05M | 18.94M | 4.47M | -3.65M |
| Operating Income Ratio | 5.19% | 5.45% | 1.86% | -2.00% |
| Total Other Income/Expenses | -3.31M | -3.55M | 2.72M | 455.44K |
| Income Before Tax | 5.74M | 15.38M | 7.19M | -3.19M |
| Income Before Tax Ratio | 3.29% | 4.43% | 2.99% | -1.75% |
| Income Tax Expense | 1.33M | 2.98M | 1.74M | 133.48K |
| Net Income | 4.41M | 12.40M | 5.45M | -3.33M |
| Net Income Ratio | 2.53% | 3.57% | 2.27% | -1.82% |
| EPS | 0.22 | 0.62 | 0.27 | -0.22 |
| EPS Diluted | 0.22 | 0.62 | 0.27 | -0.22 |
| Weighted Avg Shares Out | 20.00M | 20.00M | 20.00M | 15.00M |
| Weighted Avg Shares Out (Dil) | 20.00M | 20.00M | 20.00M | 15.00M |
Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
CAPTN-3 is a conditionally activated tri-specific antibody platform that features novel dual engagement of T cells and NK cells to mount an optimal anti-tumoral immune response against cancer
Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
Initial safety and efficacy data from fadraciclib monotherapy in patients with advanced solid tumors preselected for CDKN2A and/or CDKN2B abnormalities
Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors
– Data show that p300 KAT inhibitor KB-9558 was highly selective against human papillomavirus (HPV) oncoproteins E6 and E7, and therefore drove anti-tumor effects –
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium
PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation plenary session presentation: October 24, 2024, 10:00 AM CEST (4:00 AM EST) PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors...
Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Poster presentations include new preclinical data demonstrating activity for palazestrant in combination with capivasertib and everolimus, and OP-3136, Olema's KAT6 inhibitor, in combination with palazestrant and other targeted agents Poster presentations include new preclinical data demonstrating activity for palazestrant in...
Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast
Pancreatic ductal adenocarcinoma (PDAC) data from RMC-6236 (RAS(ON) multi-selective inhibitor) and RMC-9805 (RAS (ON) G12D-selective inhibitor) monotherapy studies to be featured in two late-breaking presentations Pancreatic ductal adenocarcinoma (PDAC) data from RMC-6236 (RAS(ON) multi-selective inhibitor) and RMC-9805 (RAS (ON) G12D-selective...
IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR Symposium
SOUTH SAN FRANCISCO, Calif. , Oct. 4, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced a late-breaking oral presentation of the Phase 1 expansion results of...
NCI Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
HONG KONG, July 09, 2024 (GLOBE NEWSWIRE) -- Neo-Concept International Group Holdings Limited (Nasdaq: NCI) (the “Company”), announced that, on July 8, 2024, the Company received a letter from the Listing Qualifications staff of The Nasdaq Stock Market ("Nasdaq") notifying...
Why Is Neo-Concept (NCI) Stock Up 61% Today?
Neo-Concept (NASDAQ: NCI ) stock is up on Thursday alongside heavy pre-market trading for the apparel solutions company's shares this morning. This has more than 13 million shares of the company's stock changing hands as of this writing.
NCI Announces Game-Changing Acquisition Turbocharges Retail Expansion
HONG KONG, May 29, 2024 (GLOBE NEWSWIRE) -- Neo-Concept International Group Holdings Limited (Nasdaq: NCI) (the “Company”), a one-stop apparel solution services provider, today announced a game-changing acquisition. The company has signed an Asset Purchase Agreement (“APA”) to acquire the...
Source: https://incomestatements.info
Category: Stock Reports